Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study

With monitoring and prophylaxis, alemtuzumab 60 mg combined with CHOP showed activity in CD52+ PTL and achieved the highest drug levels.